A Resource for Healthcare and Social Services Professionals
This event is intended to provide four hours of required training for providers seeking their buprenorphine waiver
This course comprises the first half of the eight-hour buprenorphine waiver course.
This course is intended only for Boston Medical Center's Family Medicine Residents. If you are not a Family Medicine resident but are interested in waiver training, please contact Lexie Bergeron at email@example.com.
ALL REGISTRANTS MUST COMPLETE THE SECOND FOUR HOURS ONLINE AFTER THIS EVENT. After the event, you will be sent a link to complete the second part of the eight-hour waiver training. You must complete the last four hours within 30 days of this training event and pass the online test, or you will be required to retake the full eight hours of training.
The full eight-hour waiver course prepares physicians, nurse practitioners, and physician assistants to prescribe buprenorphine to treat opioid use disorder in their office. The curriculum includes the science of addiction as a brain disorder, the pharmacology of buprenorphine, and the regulatory requirements around prescribing this medication. Attendees will learn to screen patients for treatment with buprenorphine and to manage the medication along with the patient's other medical needs in an office setting such as a primary care clinic. The course fulfills 8 hours of the training needed to obtain a waiver to prescribe buprenorphine. The Drug Addiction Treatment Act of 2000 (DATA 2000) requires physicians to complete 8 hours of approved training in order to be eligible for a waiver, and nurse practitioners and physician assistants to complete 24 hours.
Check-in for the course will be from 12:30pm- 1:00pm, and the course will run from 1:00pm-5:00pm. This is an in-person training. There will not be an option to attend via webinar.
Upon completion of the first 4 hours of training in-person and the second 4 hours of training online, the participants will be able to:
This event is intended to provide four hours of buprenorphine waiver training to the Residents of the Boston University School of Medicine.
Boston Medical Center Grayken Center for Addiction, Massachusetts Department of Public Health, Bureau of Substance Addiction Services (DPH/BSAS).
American Academy of Addiction Psychiatry (AAAP) is the DATA 2000 sponsor for this training.
Funding for this initiative was made possible (in part) by grant nos. 5U79TI026556-02 and 3U79TI026556-02S1 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
CME Accreditation: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American Academy of Addiction Psychiatry, Boston Medical Center and the Massachusetts Department of Public Health and the Bureau of Substance Abuse Services. AAAP is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation: American Academy of Addiction Psychiatry designates this Other activity (“Half and Half” - Half face-to-face live course and Half online course) for a maximum of 8 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Method of physician participation in the learning process: Credit will only be awarded for completing both the “first” and the “second” half of the training. To be awarded a maximum of 8 AMA PRA Category 1 Credits™ and a Buprenorphine Training Completion Certificate you must complete 4.25 hours of the first live half and 3.75 hours of the second enduring half and receive a minimum cumulative score of 75% on the examination. No partial credit is awarded for this training.